News and Events
A transcription factor known as Snail1 can act as a “molecular bypass” that diminishes the natural tumor suppressing action of a gene called p53 in breast cancer patients, a new study finds.
As part of the Cancer Moonshot, representatives from government, academic, pharmaceutical and diagnostic companies are launching a new partnership in pursuit of creating an open database for liquid biopsies to potentially accelerate the development of safe and effective blood profiling diagnostic technologies for patient benefit.
The University of Michigan Comprehensive Cancer Center is one of 12 sites to join Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer.
The University of Michigan Comprehensive Cancer Center has appointed four new leaders to oversee the direction and operation of its research enterprise.